Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

15.24 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,360
Open	15.24
Bid (Size)	15.16 (600)
Ask (Size)	15.30 (100)
Prev. Close	15.24
Today's Range	15.24 - 15.24
52wk Range	1.500 - 15.68
Shares Outstanding	46,772,263
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

August 11, 2026

From Pomerantz LLP

Via GlobeNewswire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 11, 2026

From Schall, Brown & Schwartz LLP

Via GlobeNewswire

Performance

YTD	+71.2%	+71.2%
1 Month	+53.4%	+53.4%
3 Month	+187.5%	+187.5%
6 Month	+96.4%	+96.4%
1 Year	+190.3%	+190.3%

More News

REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

August 10, 2026

From Kirby McInerney LLP

Via Business Wire

REPLIMUNE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Replimune Group Inc. and Encourages Investors to Contact the Firm

August 10, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Replimune Announces Pricing of $150 Million Underwritten Offering

August 10, 2026

From Replimune, Inc.

Via GlobeNewswire

Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL

August 10, 2026

From DJS Law Group

Via Business Wire

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

August 07, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Deadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

August 07, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Deadline Approaching: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

August 07, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

August 07, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Law Offices of Howard G. Smith Encourages Replimune Group, Inc. (REPL) Shareholders to Inquire About Securities Fraud Class Action

August 07, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Law Offices of Frank R. Cruz Encourages Replimune Group, Inc. (REPL) Shareholders To Inquire About Securities Fraud Class Action

August 07, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Stockholder Alert: Robbins LLP Informs Investors of the Replimune Group, Inc. Class Action

August 06, 2026

From Robbins LLP

Via Business Wire

REPL CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Replimune Group, Inc. Investors

August 06, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

August 06, 2026

From Replimune, Inc.

Via GlobeNewswire

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

August 05, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 04, 2026

From Kirby McInerney LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL

August 04, 2026

From Pomerantz LLP

Via GlobeNewswire

Top movers in Friday's session ↗

July 31, 2026

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 31, 2026

Via Benzinga

Top stock movements in today's session. ↗

July 31, 2026

Via Chartmill

Gapping stocks in Friday's session ↗

July 31, 2026

Via Chartmill

Friday's pre-market session: top gainers and losers ↗

July 31, 2026

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 31, 2026

Via Benzinga

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

July 30, 2026

From Replimune, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Replimune Group, Inc. - Common Stock publicly traded?

Yes, Replimune Group, Inc. - Common Stock is publicly traded.

What exchange does Replimune Group, Inc. - Common Stock trade on?

Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Replimune Group, Inc. - Common Stock?

The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market

What is the current price of Replimune Group, Inc. - Common Stock?

The current price of Replimune Group, Inc. - Common Stock is 15.24

When was Replimune Group, Inc. - Common Stock last traded?

The last trade of Replimune Group, Inc. - Common Stock was at 08/12/26 04:00 PM ET

What is the market capitalization of Replimune Group, Inc. - Common Stock?

The market capitalization of Replimune Group, Inc. - Common Stock is 712.81M

How many shares of Replimune Group, Inc. - Common Stock are outstanding?

Replimune Group, Inc. - Common Stock has 713M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.